SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Titan Bio-Tech Ltd

BSE: 524717 NSE: ISIN: INE150C01029
  |   Sector:  Chemicals & Fertilizers   |   Industry:  Chemicals

Snapshot

Q.1 Which industry/sub-sector does Titan Bio-Tech Ltd belong to?
Titan Bio-Tech Ltd belongs to the Chemicals & Fertilizers sector, operating specifically within the Chemicals segment.
Q.2 Is Titan Bio-Tech Ltd a good quality company?
Titan Bio-Tech Ltd is a good quality company, based on a consistently good 10 year financial track record.
Q.3 Is Titan Bio-Tech Ltd undervalued or overvalued?
Titan Bio-Tech Ltd appears Overvalued, as its key valuation ratios are above with their past averages.
Q.4 Is Titan Bio-Tech Ltd a good buy now?
Titan Bio-Tech Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Titan Bio-Tech Ltd?
Titan Bio-Tech Ltd revenue growth is -4.6% for FY-2025 , which is below its 5 year CAGR of 17.6% , indicating slower growth.
Q.2 Gross Profit margin of Titan Bio-Tech Ltd?
Titan Bio-Tech Ltd Gross profit margin which is the profit after deduction of direct costs, is 18.2% for FY-2025 , which is below its 5 year median of 21.3% , indicating decreasing margins.
Q.3 Operating Profit Margin of Titan Bio-Tech Ltd?
Titan Bio-Tech Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 16.25% for FY-2025 , which is below its 5 year median of 20.89% indicating decreasing margins.
Q.4 Net Profit Margin of Titan Bio-Tech Ltd?
Titan Bio-Tech Ltd Net Profit Margin is 11.68% for FY-2025 , is below with its 5 year median of 14.6%, indicating decreasing margins.
Current Level Historic Median
Gross Profit Margin 18.2 21.3
Operating Profit Margin 16.25 20.89
Net Profit Margin 11.68 14.6
Q.5 Return on Asset of Titan Bio-Tech Ltd?
Titan Bio-Tech Ltd Return on Asset is 11%, which is below its 5 year historical median of 16.62%, indicating deteriorated asset utilization efficiency.
Q.6 Return on Equity (ROE) of Titan Bio-Tech Ltd?
Titan Bio-Tech Ltd Return on equity is 13.36% for FY-2025 , which is below its historical median of 21.86%, indicating the business is making worse use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Titan Bio-Tech Ltd?
Titan Bio-Tech Ltd Return on capital employed is 17.8% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 14%, indicating value creation.
Q.8 Cash conversion cycle of Titan Bio-Tech Ltd?
Titan Bio-Tech Ltd Cash conversion cycle is 144 days, above its historical median of 122 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.94 1.14
ROE 13.36 21.86
ROCE 17.8 27.9
Cash Conversion Cycle 144 days 122 days
Q.9 Debt to Equity ratio of Titan Bio-Tech Ltd?
Titan Bio-Tech Ltd Debt-to-Equity ratio is 0.01 , which is lower with the industry average of 0.13 , indicating lower debt levels in the industry.
Q.10 Debt to cash flow from operations of Titan Bio-Tech Ltd?
Titan Bio-Tech Ltd Debt to cash flow from operations is 0.1 , which is at a healthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Titan Bio-Tech Ltd?
Promoters hold 55.78% of the Titan Bio-Tech Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Titan Bio-Tech Ltd vs industry peers?
Titan Bio-Tech Ltd revenue CAGR is 17.63% , compared to the industry median CAGR of 7.7% , indicating faster growth and gaining its market share.
Profit Metrics
Current Level Industry Median
Revenue 156.5 202
Gross Profit 28.4 23.6
Operating Profit 25 24
Net Profit 18 12
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.94 0.93
ROE 13.36 10.18
ROCE 17.8 13.07
Cash Conversion Cycle (days) 144.11 62

Valuation & price assessment

Q.1 Stock return of Titan Bio-Tech Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 52.6% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price 52.6% 62.2% 111.4% 379%
Q.3 Valuation ratios of Titan Bio-Tech Ltd vs historical?
The current P/E is higher that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 75.74 0.00 41.15
Price to Book 11.36 1.88 2.38
Price to Sales 9.7 1.07 1.93
EV to EBITDA 49.07 0.00 13.71

Check more companies

1. Navin Fluorine Intl
2. Godrej Industries
3. Deepak Nitrite
4. Atul
5. Tata Chemicals
6. BASF India
7. Aarti Inds
8. Aether Industries
9. Deepak Fert & Petro
10. Fine Organic Inds.
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×